222 related articles for article (PubMed ID: 21853156)
1. An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.
Chelouah S; Monod-Wissler C; Bailly C; Barret JM; Guilbaud N; Vispé S; Käs E
PLoS One; 2011; 6(8):e23597. PubMed ID: 21853156
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.
Brel V; Annereau JP; Vispé S; Kruczynski A; Bailly C; Guilbaud N
Biochem Pharmacol; 2011 Dec; 82(12):1843-52. PubMed ID: 21924246
[TBL] [Abstract][Full Text] [Related]
3. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
4. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Ballot C; Jendoubi M; Kluza J; Jonneaux A; Laine W; Formstecher P; Bailly C; Marchetti P
Apoptosis; 2012 Apr; 17(4):364-76. PubMed ID: 22127645
[TBL] [Abstract][Full Text] [Related]
5. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
6. An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quantified by comparative analysis centered on the clinical candidate F14512.
Palermo G; Minniti E; Greco ML; Riccardi L; Simoni E; Convertino M; Marchetti C; Rosini M; Sissi C; Minarini A; De Vivo M
Chem Commun (Camb); 2015 Oct; 51(76):14310-3. PubMed ID: 26234198
[TBL] [Abstract][Full Text] [Related]
7. F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.
Thibault B; Clement E; Zorza G; Meignan S; Delord JP; Couderc B; Bailly C; Narducci F; Vandenberghe I; Kruczynski A; Guilbaud N; Ferré P; Annereau JP
Cancer Lett; 2016 Jan; 370(1):10-8. PubMed ID: 26404751
[TBL] [Abstract][Full Text] [Related]
8. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.
Tierny D; Serres F; Segaoula Z; Bemelmans I; Bouchaert E; Pétain A; Brel V; Couffin S; Marchal T; Nguyen L; Thuru X; Ferré P; Guilbaud N; Gomes B
Clin Cancer Res; 2015 Dec; 21(23):5314-23. PubMed ID: 26169968
[TBL] [Abstract][Full Text] [Related]
9. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
10. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.
Kruczynski A; Vandenberghe I; Pillon A; Pesnel S; Goetsch L; Barret JM; Guminski Y; Le Pape A; Imbert T; Bailly C; Guilbaud N
Invest New Drugs; 2011 Feb; 29(1):9-21. PubMed ID: 19777159
[TBL] [Abstract][Full Text] [Related]
11. Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.
Leblond P; Boulet E; Bal-Mahieu C; Pillon A; Kruczynski A; Guilbaud N; Bailly C; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Invest New Drugs; 2014 Oct; 32(5):883-92. PubMed ID: 25008900
[TBL] [Abstract][Full Text] [Related]
12. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.
Mouawad F; Gros A; Rysman B; Bal-Mahieu C; Bertheau C; Horn S; Sarrazin T; Lartigau E; Chevalier D; Bailly C; Lansiaux A; Meignan S
Oral Oncol; 2014 Feb; 50(2):113-9. PubMed ID: 24290982
[TBL] [Abstract][Full Text] [Related]
13. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A
Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
15. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Kruczynski A; Pillon A; Créancier L; Vandenberghe I; Gomes B; Brel V; Fournier E; Annereau JP; Currie E; Guminski Y; Bonnet D; Bailly C; Guilbaud N
Leukemia; 2013 Nov; 27(11):2139-48. PubMed ID: 23568148
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.
Sathish M; Kavitha B; Nayak VL; Tangella Y; Ajitha A; Nekkanti S; Alarifi A; Shankaraiah N; Nagesh N; Kamal A
Eur J Med Chem; 2018 Jan; 144():557-571. PubMed ID: 29289881
[TBL] [Abstract][Full Text] [Related]
17. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
[TBL] [Abstract][Full Text] [Related]
18. One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
Shankaraiah N; Kumar NP; Amula SB; Nekkanti S; Jeengar MK; Naidu VG; Reddy TS; Kamal A
Bioorg Med Chem Lett; 2015 Oct; 25(19):4239-44. PubMed ID: 26292628
[TBL] [Abstract][Full Text] [Related]
19. Increasing the distance between two monomers of topoisomerase IIβ under the action of antitumor agent 4β-sulfur-(benzimidazole) 4'-demethylepipodophyllotoxin.
Sun LY; Zhu LW; Tang YJ
Sci Rep; 2018 Oct; 8(1):14949. PubMed ID: 30297860
[TBL] [Abstract][Full Text] [Related]
20. 5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis.
Xu D; Cao J; Qian S; Li L; Hu C; Weng Q; Lou J; Zhu D; Zhu H; Hu Y; He Q; Yang B
Invest New Drugs; 2011 Oct; 29(5):786-99. PubMed ID: 20352292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
